More about
Bipolar Disorder
News
March 24, 2020
3 min read
Save
Genes largely responsible for bipolar disorder transmission across generations
News
February 28, 2020
2 min read
Save
BLOG: Concussions, depression and the eyes – it’s all connected
News
February 13, 2020
2 min read
Save
Five new subgroups may change psychosis taxonomy
News
January 31, 2020
1 min read
Save
Top 5 psychiatry stories of January
News
January 20, 2020
2 min read
Save
Voice-analysis application assesses well-being of patients with serious mental illness
News
January 16, 2020
2 min read
Save
Family-focused therapy reduces mood episodes in youths at risk for bipolar disorder
News
January 09, 2020
2 min read
Save
BMI linked to major psychiatric disorders
News
December 26, 2019
2 min read
Save
Air pollution exposure may increase risk for depression, suicide
News
December 19, 2019
2 min read
Save
Having dogs as pets may decrease schizophrenia risk
News
December 17, 2019
2 min read
Save
Q&A: Treatment potential of ALKS 3831 for schizophrenia, bipolar I disorder

Alkermes recently announced submission of a new drug application to the FDA for its investigational schizophrenia treatment ALKS 3831, a combination of olanzapine and samidorphan, for the treatment of schizophrenia and the treatment of bipolar I disorder. If approved, the drug is intended to provide the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain.